Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Quince Therapeutics已對共濟失調-毛細血管擴張患者中使用EryDex進行第3期NEAT試驗的第一位患者進行了給藥，拓撲線結果預計在2025年下半年公佈，並有可能在2026年遞交新藥申請。
Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Quince Therapeutics已對共濟失調-毛細血管擴張患者中使用EryDex進行第3期NEAT試驗的第一位患者進行了給藥，拓撲線結果預計在2025年下半年公佈，並有可能在2026年遞交新藥申請。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。